Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387136070> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4387136070 abstract "<h3>Introduction/Background</h3> Ovarian cancer is the fifth leading cause of death of women in the United Kingdom, with most of these deaths being attributed to high-grade serous ovarian carcinomas (HGS-OvCa). Ovarian cancer responds well to treatment with chemotherapy often achieving complete clinical, radiological and marker response. However, unfortunately many women relapse and require further treatment. Treatment that reduces the risk of relapse would provide a major step in the treatment of ovarian cancer. <h3>Methodology</h3> A systematic search was conducted of three databases; PubMed, Scopus and MEDLINE. The terms ‘ovarian cancer’, ‘PARP inhibitors’ and ‘platinum’ were added to the databases in order to narrow down the search results. Inclusion criteria were phase 2 and phase 3 trials, both BRCA and non-BRCA mutations, good response to platinum therapy, paper in the English language and published within the last 10 years. Primary endpoints include the progression free survival and tolerability towards treatment. <h3>Results</h3> Benefit is seen in all groups of patients although the greatest benefit is seen in patients with BRCA mutations. For trials of niraparib, olaparib and rucaparib, the median months of progression-free survival increased by an average of 15.5 months, 13.6 months, and 11.2 months respectively. The treatment is well tolerated with the studies showing no compromise of quality of life compared to patients in the control arms who received placebo. Dose adjustment was required in a small proportion of patients and less than 15% of patients discontinued treatment due to adverse effects,. <h3>Conclusion</h3> This systematic review supports the use of PARP inhibitors in the maintenance of response following treatment with platinum-based chemotherapy in patients with relapsed ovarian cancer. However, longer follow up is required to assess whether these encouraging results and the improvement in progression free survival will translate into improvement in overall survival. <h3>Disclosures</h3> None to disclose." @default.
- W4387136070 created "2023-09-29" @default.
- W4387136070 creator A5074929015 @default.
- W4387136070 date "2023-09-01" @default.
- W4387136070 modified "2023-09-29" @default.
- W4387136070 title "#39 The role of PARP inhibitors in the maintenance of response in platinum sensitive recurrent ovarian cancers" @default.
- W4387136070 doi "https://doi.org/10.1136/ijgc-2023-esgo.500" @default.
- W4387136070 hasPublicationYear "2023" @default.
- W4387136070 type Work @default.
- W4387136070 citedByCount "0" @default.
- W4387136070 crossrefType "proceedings-article" @default.
- W4387136070 hasAuthorship W4387136070A5074929015 @default.
- W4387136070 hasBestOaLocation W43871360701 @default.
- W4387136070 hasConcept C104317684 @default.
- W4387136070 hasConcept C121608353 @default.
- W4387136070 hasConcept C126322002 @default.
- W4387136070 hasConcept C143998085 @default.
- W4387136070 hasConcept C182979987 @default.
- W4387136070 hasConcept C185592680 @default.
- W4387136070 hasConcept C197934379 @default.
- W4387136070 hasConcept C2776694085 @default.
- W4387136070 hasConcept C2778375690 @default.
- W4387136070 hasConcept C2779962180 @default.
- W4387136070 hasConcept C2780194787 @default.
- W4387136070 hasConcept C2780427987 @default.
- W4387136070 hasConcept C2780739268 @default.
- W4387136070 hasConcept C535046627 @default.
- W4387136070 hasConcept C55493867 @default.
- W4387136070 hasConcept C71924100 @default.
- W4387136070 hasConcept C82381507 @default.
- W4387136070 hasConceptScore W4387136070C104317684 @default.
- W4387136070 hasConceptScore W4387136070C121608353 @default.
- W4387136070 hasConceptScore W4387136070C126322002 @default.
- W4387136070 hasConceptScore W4387136070C143998085 @default.
- W4387136070 hasConceptScore W4387136070C182979987 @default.
- W4387136070 hasConceptScore W4387136070C185592680 @default.
- W4387136070 hasConceptScore W4387136070C197934379 @default.
- W4387136070 hasConceptScore W4387136070C2776694085 @default.
- W4387136070 hasConceptScore W4387136070C2778375690 @default.
- W4387136070 hasConceptScore W4387136070C2779962180 @default.
- W4387136070 hasConceptScore W4387136070C2780194787 @default.
- W4387136070 hasConceptScore W4387136070C2780427987 @default.
- W4387136070 hasConceptScore W4387136070C2780739268 @default.
- W4387136070 hasConceptScore W4387136070C535046627 @default.
- W4387136070 hasConceptScore W4387136070C55493867 @default.
- W4387136070 hasConceptScore W4387136070C71924100 @default.
- W4387136070 hasConceptScore W4387136070C82381507 @default.
- W4387136070 hasLocation W43871360701 @default.
- W4387136070 hasOpenAccess W4387136070 @default.
- W4387136070 hasPrimaryLocation W43871360701 @default.
- W4387136070 hasRelatedWork W2561042858 @default.
- W4387136070 hasRelatedWork W2609703182 @default.
- W4387136070 hasRelatedWork W2623797673 @default.
- W4387136070 hasRelatedWork W2900951833 @default.
- W4387136070 hasRelatedWork W2942893873 @default.
- W4387136070 hasRelatedWork W3040343436 @default.
- W4387136070 hasRelatedWork W3047344552 @default.
- W4387136070 hasRelatedWork W3163054128 @default.
- W4387136070 hasRelatedWork W3191066603 @default.
- W4387136070 hasRelatedWork W4286293806 @default.
- W4387136070 isParatext "false" @default.
- W4387136070 isRetracted "false" @default.
- W4387136070 workType "article" @default.